Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Phase 1

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Dabrafenib
Drug: Trametinib
Drug: Phenformin

First Posted Date: 2017-01-20

Last Posted Date: 2024-02-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT03026517

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer
Endometrial Carcinosarcoma
Endometrial Carcinoma
Endometrial Cancer Recurrent
Endometrial Carcinoma, Recurrent

Interventions: Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2017-01-09

Last Posted Date: 2024-02-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 80

Registration Number: NCT03015129

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Study of Cognitive Behavioral Therapy for Insomnia (CBT-I) and Acupuncture for Insomnia and Related Distress Among Cancer Caregivers

Not Applicable

Completed

Conditions: Related Distress Among Cancer Caregivers
Insomnia

Interventions: Procedure: Acupuncture
Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Behavioral: questionnaires
Other: Diurnal Cortisol

First Posted Date: 2017-01-06

Last Posted Date: 2021-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT03012425

Locations: 🇺🇸
Hunter College, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of California, Irvine, Irvine, California, United States

Taxi STEP (Social Networks, Technology, and Exercise Through Pedometers)

Not Applicable

Active, not recruiting

Conditions: Physical Conditioning

Interventions: Other: Health Fair
Other: Pedometer
Other: Text Messaging
Other: Social Network Support

First Posted Date: 2017-01-04

Last Posted Date: 2024-07-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 290

Registration Number: NCT03010163

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Mobile Health Device Study for Myeloma Patients

Completed

Conditions: Multiple Myeloma
Myeloma

Interventions: Device: Garmin Vivofit device
Behavioral: Mobile Health quality of life assessements

First Posted Date: 2016-12-30

Last Posted Date: 2024-11-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT03006315

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 2 locations

Feasibility Testing of a Novel Endoscope for Reflectance Confocal Microscopy of Normal Oral Tissue In Vivo

Completed

Conditions: Oral Tissue

Interventions: Device: Reflectance Confocal Microscopy (RCM) endoscope device

First Posted Date: 2016-12-28

Last Posted Date: 2022-03-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT03004053

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Phase II Study of Atezolizumab in Combination with Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1

Active, not recruiting

Conditions: Bladder Cancer
Metastatic Bladder Cancer
Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2016-12-12

Last Posted Date: 2024-10-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 54

Registration Number: NCT02989584

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States

and more 8 locations

PEACE: Comparing Chronic Pain Treatment Options

Not Applicable

Active, not recruiting

Conditions: Pain Management
Chronic Pain
Fibromyalgia
Musculoskeletal Pain

Interventions: Procedure: Electro-Acupuncture (EA)
Procedure: Battle Field Acupuncture (BFA)
Device: Wait List Control (WLC)

First Posted Date: 2016-12-01

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 360

Registration Number: NCT02979574

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

and more 4 locations

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Drug: Ruxolitinib

First Posted Date: 2016-11-28

Last Posted Date: 2024-11-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 82

Registration Number: NCT02974647

Locations: 🇺🇸
Northwestern Medicine (Data collection and specimen analysis), Chicago, Illinois, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 7 locations

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Early Phase 1

Terminated

Conditions: Follicular Lymphoma, Grade 2
Follicular Lymphoma, Grade 1
Follicular Lymphoma Grade IIIa
Follicular Lymphoma

Interventions: Drug: Ibrutinib

First Posted Date: 2016-11-17

Last Posted Date: 2019-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT02966730

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy